Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetRevenue - OtherShares OutstandingShares Outstanding
Ratios

Aclaris Therapeutics (ACRS) Cost of Revenue (2017 - 2025)

Aclaris Therapeutics has reported Cost of Revenue over the past 9 years, most recently at $532000.0 for Q4 2025.

  • Quarterly results put Cost of Revenue at $532000.0 for Q4 2025, down 24.54% from a year ago — trailing twelve months through Dec 2025 was $2.1 million (down 25.11% YoY), and the annual figure for FY2025 was $2.1 million, down 25.11%.
  • Cost of Revenue for Q4 2025 was $532000.0 at Aclaris Therapeutics, down from $538000.0 in the prior quarter.
  • Over the last five years, Cost of Revenue for ACRS hit a ceiling of $1.3 million in Q2 2021 and a floor of $506000.0 in Q1 2025.
  • Median Cost of Revenue over the past 5 years was $828500.0 (2023), compared with a mean of $852100.0.
  • Peak annual rise in Cost of Revenue hit 0.12% in 2024, while the deepest fall reached 40.12% in 2024.
  • Aclaris Therapeutics' Cost of Revenue stood at $1.1 million in 2021, then decreased by 23.67% to $877000.0 in 2022, then decreased by 17.33% to $725000.0 in 2023, then decreased by 2.76% to $705000.0 in 2024, then decreased by 24.54% to $532000.0 in 2025.
  • The last three reported values for Cost of Revenue were $532000.0 (Q4 2025), $538000.0 (Q3 2025), and $515000.0 (Q2 2025) per Business Quant data.